NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO)
$4.86
-0.1450 ( -2.90% ) 40.8K
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
Market Data
Open
$4.86
Previous close
$5.00
Volume
40.8K
Market cap
$48.28M
Day range
$4.78 - $4.98
52 week range
$2.90 - $6.75
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 42 | Apr 16, 2024 |
8-k | 8K-related | 16 | Apr 01, 2024 |
8-k | 8K-related | 16 | Mar 28, 2024 |
10-k | Annual reports | 92 | Mar 28, 2024 |
8-k | 8K-related | 17 | Mar 13, 2024 |
8-k | 8K-related | 18 | Mar 04, 2024 |
4 | Insider transactions | 1 | Mar 04, 2024 |
8-k | 8K-related | 17 | Feb 29, 2024 |
8-k | 8K-related | 42 | Feb 14, 2024 |
8-k | 8K-related | 17 | Feb 01, 2024 |